Lifevantage (NASDAQ: LFVN) reported Q2 EPS of $0.31, $0.15 better than the analyst estimate of $0.16. Revenue for the quarter came in at $61.2 million versus the consensus estimate of $64.09 million.

Second Quarter Fiscal 2020 Summary*:

• Revenue increased 5.3% to $61.2 million;
• Revenue in the Americas increased 4.3% and revenue in Asia/Pacific & Europe increased 7.8%, including 4.7% growth in Japan;
• Total active accounts increased 0.6% sequentially to 182,000, while declining year over year by 1.1%. The sequential growth included a 4.6% increase in distributors, partially offset by a 1.7% decline in customers. On year over year basis, distributors increased 3.0% and customers declined 3.4%;
• Adjusted EBITDA increased 82.2% to $6.0 million;
• Earnings per diluted share were $0.30, compared to $0.06 in the prior year period;
• Adjusted earnings per diluted share increased 138.5% to $0.31, compared to $0.13 in the prior year period; and
• Repurchased $2.0 million of common shares during the second quarter of fiscal 2020.

"We are pleased with our strong revenue growth and profit performance during the second quarter. We generated over 5% year over year revenue growth, 82% year over year growth of adjusted EBITDA and 138% adjusted EPS growth over the prior year period,” stated LifeVantage President and Chief Executive Officer, Darren Jensen. “The U.S. launch of our newest addition to our flagship Protandim® product line, Protandim® NAD Synergizer™, was a significant success and lifted sales across our entire family of Protandim® products during the quarter. We continue to see a strong consumer response to our recent launch and are focused on driving subscription orders of both our Protandim® NAD Synergizer™ and our newly introduced Protandim® Tri-Synergizer™ bundle. Additionally, we saw strong sales growth in our Asia Pacific and Europe region, particularly within Japan where sales increased 5%. We also enjoyed a strong launch in New Zealand during the quarter, leveraging our existing business in Australia."

"We remain on track to meet our fiscal 2020 expectations for both revenue and adjusted EBITDA, and are increasing our fiscal 2020 adjusted EPS guidance. We remain confident in our business and will continue to execute upon each of our 2020 initiatives to drive growth, margin performance and shareholder value," continued Mr. Jensen.

GUIDANCE:

Lifevantage sees FY2020 EPS of $0.74-$0.79, versus the consensus of $0.70. Lifevantage sees FY2020 revenue of $235-245 million, versus the consensus of $245 million.

The Company is reiterating its outlook for fiscal 2020 revenue and adjusted EBITDA, which was initially provided when the Company reported fourth fiscal quarter and full fiscal year 2019 results on August 14, 2019. The Company expects to generate revenue in the range of $235 million to $245 million in fiscal year 2020 and adjusted EBITDA of $20 million to $22 million. The Company is raising its adjusted earnings per share to a range of $0.74 to $0.79, up from $0.62 to $0.71 previously, which now reflects a full year tax rate of approximately 17% compared to the prior range of 19% to 22%, as well as a reduction in our estimated annual fully diluted share count. The Company's adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share guidance excludes any non-operating or non-recurring expenses that may materialize during fiscal 2020. The Company is not providing GAAP earnings per diluted share guidance for fiscal 2020 due to the potential occurrence of one or more non-operating, one-time expenses, which the Company does not believe it can reliably predict.

For earnings history and earnings-related data on Lifevantage (LFVN) click here.